

Report on the WHO Quantitative Immunization and Vaccines Related Research (QUIVER)

**Advisory Committee Meeting
5-7 October 2010
Geneva, Switzerland**

Immunization, Vaccines and Biologicals



**World Health
Organization**

Report on the WHO Quantitative Immunization and Vaccines Related Research (QUIVER)

**Advisory Committee Meeting
5-7 October 2010
Geneva, Switzerland**

Immunization, Vaccines and Biologicals



**World Health
Organization**

**The Department of Immunization, Vaccines and Biologicals
thanks the donors whose unspecified financial support
has made the production of this document possible.**

This document was produced by the
Initiative for Vaccine Research (IVR)
of the Department of Immunization, Vaccines and Biologicals

Ordering code: WHO/IVB/11.06
Printed: July 2011

This publication is available on the Internet at:
www.who.int/vaccines-documents/

**Copies of this document as well as additional materials on
immunization, vaccines and biologicals may be requested from:**

World Health Organization
Department of Immunization, Vaccines and Biologicals
CH-1211 Geneva 27, Switzerland

• *Fax:* + 41 22 791 4227 • *Email:* vaccines@who.int •

© World Health Organization 2011

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

The named authors alone are responsible for the views expressed in this publication.

Printed by the WHO Document Production Services, Geneva, Switzerland

Contents

<i>Abbreviations and acronyms</i>	<i>v</i>
<i>Executive Summary</i>	<i>vii</i>
1. Introduction and Charge to the Committee	1
2. WHO-CHERG estimates of child causes of death - Introduction	2
2.1 CHERG model	2
2.2 WHO process for preparing consistent child causes of death estimates	3
2.3 Summary points and recommendations	4
3. Burden of pertussis model	5
3.1 Pertussis model structure and expert elicitation	5
3.2 Summary points and recommendations	6
4. Estimating the burden of measles	7
Introduction	7
4.1 Measles model	7
4.2 Summary points and recommendations	8
5. Immunisation schedules	9
5.1 Generic approach – systematic review	9
5.2 Specific model of PCV schedules	10
5.3 Summary points and recommendations	12
6. For information updates	14
6.1 Rotavirus burden estimates	14
6.2 HPV cost-effectiveness tool comparison	15
6.3 Modelling supply chain logistics and impact on health outcomes	15
6.4 Workshop on dengue vaccine modelling	16
6.5 Influenza social contacts and mixing patterns in South East Asia	17
6.6 Measles and rubella modelling	18
7. Malaria vaccine modelling	19
7.1 Evaluating the cost-effectiveness of malaria vaccines: a review of modelling tools	19
7.2 Summary points and recommendations	20

8. Update on the feasibility of measles eradication.....	21
8.1 LSHTM study on impact of immunization and health systems	21
8.2 Cost-effectiveness of measles elimination (model 1).....	22
8.3 Cost-effectiveness of measles elimination (model 2).....	22
8.4 Summary points and discussions.....	24
9. Other business.....	25
9.1 Working groups	25
9.2 Broader economic impact of vaccines and immunization.....	25
9.3 Mortality estimation.....	25
9.4 QUIVER terms of reference.....	26
10. Meeting agenda	27
11. List of participants.....	30

Abbreviations and acronyms

BMGF	Bill and Melinda Gates Foundation
CEA	cost-effectiveness analysis
CFR	case-fatality rate
CHERG	Child Health Epidemiology Reference Group
EPI	Expanded Programme on Immunisation
HIS	Health Statistics and Informatics (WHO)
HPV	Human Papillomavirus
IHME	Institute of Health Metrics and Evaluation
IARC	International Agency for Research on Cancer
IVB	Immunization, Vaccines and Biologicals (WHO)
IVR	Initiative for Vaccine Research (IVR)
JHSPH	John Hopkins School of Public Health
JTEG	Joint Technical Expert Group
LSHTM	London School of Hygiene and Tropical Medicine
PCV	pneumococcal conjugate vaccine
PCV7	7-valent pneumococcal conjugate vaccine
SAGE	Strategic Advisory Group of Experts of Immunization (WHO)
SIA	Special Immunisation Activity
QUIVER	Quantitative Immunization and Vaccines Related Research
SAGE	Strategic Advisory Group of Experts on Immunization
UNDP	United Nations Development Programme
UNFPA	United Nations Food
UNICEF	United Nations Children's Fund
VMI	Vaccine Modelling Initiative
WHA	World Health Assembly
WHO	World Health Organization

Executive Summary

The fourth annual meeting of the WHO Quantitative Immunization and Vaccine-Related Research (QUIVER) advisory committee was held in October 2010 in Geneva. The 12 members of the advisory committee provide advice to WHO on estimates of the burden of vaccine-preventable diseases, mathematical modeling related to vaccines and immunization programmes, estimates of the impact of vaccines, economic evaluations of vaccines and immunization programmes, and other quantitative methods of generating information relevant to policy decisions about the introduction of vaccines. The demands on QUIVER have been growing as a result of the increasing emphasis being placed on evidence-based policy-making.

Several groups within WHO (for example, the departments of Health Statistics and Informatics (HIS), and Immunization, Vaccines and Biologicals (IVB)) and outside WHO (for example, the Institute for Health Metrics and Evaluation (IHME)) have methods for estimating worldwide cause-specific childhood mortality. Each method has its strengths and weaknesses, but all focus on a single cause of death despite the fact that many people die from multiple interacting factors. QUIVER recommends that methods for estimating childhood mortality reflect the multi-cause nature of many deaths and the uncertainty of point estimates. QUIVER recommends that the activities on estimation of childhood mortality carried out by the WHO Child Health Epidemiology Reference Group (CHERG) and IVB be coordinated, particularly in terms of harmonizing total deaths with deaths attributed to a specific condition when there are multiple causes of death. QUIVER recommends that an independent group review the methods used by entities within and outside WHO to estimate child mortality, and clarify the uncertainties around point estimates, so that general audiences understand why estimates of child mortality may differ.

A natural-history model of pertussis is being developed by the Ontario Agency for Health Protection and Promotion in Canada in collaboration with WHO to estimate

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_28698

